We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$22.8B
AUM Growth
-$295M
Cap. Flow
-$688M
Cap. Flow %
-3.02%
Top 10 Hldgs %
81.57%
Holding
135
New
6
Increased
16
Reduced
10
Closed
15

Top Buys

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$58.8M
2
LEGN icon
Legend Biotech
LEGN
+$52.6M
3
HRTX icon
Heron Therapeutics
HRTX
+$34M
4
JBIO
Jade Biosciences
JBIO
+$32.6M
5
APLS
Apellis Pharmaceuticals
APLS
+$30.9M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$611M
2
NVTA
Invitae Corporation
NVTA
+$179M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$33.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$32.4M
5
ALT icon
Altimmune
ALT
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.74%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$7.47B 32.79%
47,288,259
+17,500
+0% +$2.6M
ONC
2
BeOne Medicines Ltd
ONC
$33.8B
$4B 17.59%
11,668,897
– –
INCY icon
3
Incyte
INCY
$25.5B
$2.69B 11.83%
32,021,732
+20,345
+0.1% +$1.7M
KOD icon
4
Kodiak Sciences
KOD
$2.4B
$1.31B 5.77%
14,137,881
+257,929
+2% +$24.8M
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.43B
$1.02B 4.49%
41,910,704
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12B
$633M 2.78%
7,589,294
– –
ASND icon
7
Ascendis Pharma A/S
ASND
$16.7B
$466M 2.05%
3,540,270
– –
NVTA
8
DELISTED
Invitae Corporation
NVTA
$346M 1.52%
10,248,575
-5,500,607
-35% -$179M
ARGX icon
9
argenx
ARGX
$55.1B
$337M 1.48%
1,119,557
– –
PRLD icon
10
Prelude Therapeutics
PRLD
$347M
$290M 1.27%
10,123,824
– –
IGMS
11
DELISTED
IGM Biosciences
IGMS
$263M 1.15%
3,156,102
– –
ABCL icon
12
AbCellera Biologics
ABCL
$1.62B
$230M 1.01%
10,450,180
– –
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$228M 1%
1,409,784
– –
BCRX icon
14
BioCryst Pharmaceuticals
BCRX
$2.43B
$201M 0.88%
12,710,818
– –
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$12.5B
$146M 0.64%
1,499,213
– –
APLS
16
DELISTED
Apellis Pharmaceuticals
APLS
$144M 0.63%
2,271,917
+597,913
+36% +$30.9M
HRTX icon
17
Heron Therapeutics
HRTX
$91.6M
$126M 0.55%
8,131,678
+2,136,974
+36% +$34M
AMRN
18
Amarin Corp
AMRN
$299M
$116M 0.51%
1,322,671
– –
GBT
19
DELISTED
Global Blood Therapeutics, Inc.
GBT
$113M 0.49%
3,217,441
– –
PACB icon
20
Pacific Biosciences
PACB
$432M
$112M 0.49%
3,201,972
– –
IMCR icon
21
Immunocore
IMCR
$1.68B
$98.4M 0.43%
2,520,730
– –
KYMR icon
22
Kymera Therapeutics
KYMR
$8.6B
$95M 0.42%
1,959,211
– –
VSTM icon
23
Verastem
VSTM
$517M
$87.5M 0.38%
1,790,969
+372,694
+26% +$15.5M
VERV
24
DELISTED
Verve Therapeutics
VERV
$85.3M 0.37%
+1,416,530
New +$58.8M
TLIS
25
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$83.5M 0.37%
504,989
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Baker Bros. Advisors held 135 positions worth $22.8B, down 1.3% from $23.1B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors withdrew a net $688M in Q2 2021, closing 15 positions and reducing 10 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $611M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials.

Against the trend, Baker Bros. Advisors opened a new position in Verve Therapeutics worth $85.3M.

  • Baker Bros. Advisors's largest Q2 2021 buy was Verve Therapeutics: 1,416,530 shares worth $85.3M.
  • Baker Bros. Advisors added most to Legend Biotech in Q2 2021, an estimated $52.6M increase.
  • Baker Bros. Advisors's biggest Q2 2021 reduction was Invitae Corporation, cutting an estimated $179M.
  • Baker Bros. Advisors fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $611M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $22.8B portfolio in Q2 2021.
  • Baker Bros. Advisors opened 6 new positions and closed 15 in Q2 2021.
  • Baker Bros. Advisors's portfolio value fell 1.3% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.